{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-23-000022","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.843167+00:00","generated_at":"2026-06-19T19:13:22.571974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dexcom Q4 revenue $815.2M (+17% YoY); G7 CGM FDA cleared; guides 2023 rev $3.35-3.49B","bullets":["Q4 2022 revenue $815.2M (+17% reported, +20% organic); U.S. +17%, international +15% (organic +27%).","GAAP operating income $125.4M (15.4% margin) vs $0.6M in Q4 2021; non-GAAP operating income $172.1M (21.1% margin).","GAAP EPS $0.22 diluted; non-GAAP EPS $0.34 diluted; cash & marketable securities $2.46B.","FDA cleared Dexcom G7 CGM for ages 2+; rollout in U.S. market in 2023.","FY2023 guidance: revenue $3.35-3.49B (15-20% growth); non-GAAP gross margin 62-63%; non-GAAP op margin ~16.5%; Adj. EBITDA margin ~26%."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-23-000022","json":"https://secwatch.observer/filing/0001093557-23-000022.json","markdown":"https://secwatch.observer/filing/0001093557-23-000022.md","text":"https://secwatch.observer/filing/0001093557-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355723000022/0001093557-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355723000022/dxcm-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T19:13:22.571974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb2e94e584c34b4c28623d42f57bb7952d05b8c0","claim":"DEXCOM INC updated its quarter and year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"issued a press release announcing its financial results for the quarter and year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355723000022/0001093557-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}